Compare BTU & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTU | TARS |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | 6600 | N/A |
| Industry | Coal Mining | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.7B |
| IPO Year | 2001 | 2020 |
| Metric | BTU | TARS |
|---|---|---|
| Price | $22.88 | $58.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | $32.83 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 2.3M | 1.4M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.09% | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,861,500,000.00 | $451,360,000.00 |
| Revenue This Year | $17.96 | $56.43 |
| Revenue Next Year | $5.47 | $30.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $14.25 | $38.51 |
| 52 Week High | $41.14 | $85.25 |
| Indicator | BTU | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 42.21 | 45.13 |
| Support Level | $21.96 | $56.05 |
| Resistance Level | $24.53 | $67.14 |
| Average True Range (ATR) | 0.95 | 3.54 |
| MACD | 0.15 | -0.35 |
| Stochastic Oscillator | 31.91 | 23.72 |
Peabody Energy Corp is a producer of metallurgical and thermal coal. It also markets and brokers coal, both as principal and agent, and trades coal and freight-related contracts. The company operates in the following segment: Seaborne Thermal, Seaborne Metallurgical, Powder River Basin, Other U.S. Thermal and Corporate and Other. The Seaborne Thermal segment generates the majority of the revenue for the company. A substantial part of its overall revenue is generated from its customers in the United States, and rest from Japan, China, Australia, Taiwan, and other regions.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.